Concepedia

Stephen Chuan-Hao Kao

SC

Statistics

Publications

4

Citations

332

H-Index

4

Active since

2017

Affiliations

Chris O’Brien Lifehouse(Current)

Yonsei University

Seoul National University Bundang Hospital

Asan Medical Center

Stephen Chuan-Hao Kao is an author at Chris O’Brien Lifehouse specializing in oncology, cancer therapeutics, and molecular oncology.

Top concepts

MedicineOncologyCancer TherapyMolecular OncologyRadiation OncologyHealthNeurologyPathologyNeuro-oncologyCancer Research

Publications per year

2017–2018

4

Publications

4

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao et al. · Journal of Clinical Oncology · 2018 · 206 citations

Sclc Pts, Immunology, Immunoediting +16

Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

James Chih‐Hsin Yang, Byoung Chul Cho, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2017 · 94 citations

Leptomeningeal Metastases, Pathology, Neuro-oncology +19

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

Myung‐Ju Ahn, Dong‐Wan Kim, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2017 · 17 citations

Pathology, Pharmacotherapy, High-grade Gliomas +22

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

Byoung Chul Cho, Myung‐Ju Ahn, Jong-Seok Lee et al. · Journal of Clinical Oncology · 2017 · 15 citations

Cancer Management, Pathology, Other Anti-cancer Therapy +22

1–4 of 4